Stock Price Quote

ALPA LABORATORIES LTD.

NSE : ALPABSE : 532878ISIN CODE : INE385I01010Industry : Pharmaceuticals & DrugsHouse : Private
BSE102.75-0.95 (-0.92 %)
PREV CLOSE ( ) 103.70
OPEN PRICE ( ) 106.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 604
TODAY'S LOW / HIGH ( )102.60 106.95
52 WK LOW / HIGH ( )82.2 144.6
NSE102.92-0.86 (-0.83 %)
PREV CLOSE( ) 103.78
OPEN PRICE ( ) 103.79
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 13380
TODAY'S LOW / HIGH( ) 102.21 104.34
52 WK LOW / HIGH ( )86.31 144.5
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1988
Management Info
Mahendra Singh Chawla - Chairman Paresh Chawla - Managing Director
Registered Office

Address 33/2 Pigdamber,A B Road ,Rau,
Indore Dist,
Madhya Pradesh-453446

Phone 0731-4294567

Email mail@alpalabs.in

Website www.alpalabs.in

Registrars Details
Bigshare Services Pvt Ltd
Office No S6-2, 6th Floor, Pinnacle Business Park,Next to Ahura Centre, Mahakali Caves Road,Andheri (E),Mumbai
Listing : BSE, NSE

NEWS

05Jul Alpa Laboratories informs about disclo
Alpa Laboratories has informed that the exchange has received the disclo..
27Jun Alpa Laboratories informs about annual
Alpa Laboratories has informed that it enclosed enclosed Annual Secretar..
20Jun Alpa Laboratories informs about disclo
Alpa Laboratories has informed that the exchange has received the disclo..
18Jun Alpa Laboratories informs about discl
Alpa Laboratories has informed that the exchange has received the disclo..
02Jan Alpa Laboratories informs about closur
Pursuant of Securities and Exchange Board of India (Prohibition of Insid..

Financials

in Millions
QTR Mar 25 ANNUAL 25
Net Profit-19.4800000000001196.8
Gross Profit 22.4999999999999 258.42
Operating Profit 28.8099999999999283.1
Net Sales 391.121116.45

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  14601.10 (18.65%)
M.Cap ( in Cr)18733.05
Mankind Pharma (BSE)
peergroup  2699.80 (4.72%)
M.Cap ( in Cr)111428.51
Torrent Pharma (BSE)
peergroup  3407.05 (2.83%)
M.Cap ( in Cr)115310.05
Bharat Parenterals (BSE)
peergroup  1498.50 (4.97%)
M.Cap ( in Cr)1032.76
Wockhardt (BSE)
peergroup  1818.90 (3.54%)
M.Cap ( in Cr)29554.50

Shareholding Pattern

PROMOTERS 57.29%
NON-INSTITUTION 42.34%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Alpa Laboratories Ltd.

Alpa Laboratories Ltd. was incorporated in the year 1988. Its today's share price is 102.75. Its current market capitalisation stands at Rs 216.19 Cr. In the latest quarter, company has reported Gross Sales of Rs. 1087.39 Cr and Total Income of Rs.1236.13 Cr. The company's management includes Srashti Chopra, Sanket Baheti, Vitthal Kothana, Jyoti Jain, Pratibha Lunawat, Sunil Valecha, Shitul Shah, Pravin Shah, Paresh Chawla, Mahendra Singh Chawla.

It is listed on the BSE with a BSE Code of 532878 , NSE with an NSE Symbol of ALPA and ISIN of INE385I01010. It's Registered office is at 33/2 Pigdamber,A B Road ,RauIndore Dist-453446, Madhya Pradesh. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Anuradha Ratnaparkhi & Associates, CH Padliya & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.